New AppNote Available: SARS-CoV-2 cross-reactivity upon infection & vaccination
Published on 20/12/2021
We are happy to present a new application note by L. Loyal and A. Thiel from the Charité Universitätsmedizin Berlin, Germany
The authors show that HCoV-reactive CD4+ T cells with some being SARS-CoV-2-cross-reactive are ubiquitous but decrease with age. They identified a universal immune dominant HCoV-specific spike peptide (S816-830). Spike protein cross-reactive T cells were activated after primary BNT162b2 (Comirnaty®) COVID19 mRNA vaccination. The results highlight the functional contribution of pre-existing spike cross-reactive T cells in SARS-CoV-2 infection and vaccination.
For further reading consider checking out Application Notes , e.g. “Peptide Tools to Support the Fight against COVID-19” and References.
To use any of the products applied in the before mentioned publication, we refer you to our various products to study SARS-CoV-2.
As always, we welcome any feedback and comments.